P ulmonary hypertension (PH) is a devastating disease that leads to progressive right heart failure, disability, and death. Despite persistent efforts over the last several decades to develop effective therapies, limited progress has been made in improving quality of life, preventing, or arresting the progression of PH. The limited success of therapeutics could be because of the long-held dogma that PH is primarily a disease of the pulmonary vasculature. However, it has recently been suggested that PH should be approached as a systemic disease for the development of the next generation of therapy.
systemic hypertension. 10 Collectively, these observations raise the potential involvement of microglial cells and neuroinflammation in PH. Consistent with this view is evidence of the involvement of SNA in other pulmonary diseases. 11, 12 The rationales for focusing on the paraventricular nucleus (PVN) of the hypothalamus are (1) PVN is a key autonomic control center in the brain implicated in integrating SNA 13, 14 and a site implicated in the neurogenic origin of hypertension. 10 (2) Our studies in systemic hypertension have shown association of activated microglial cells and neuroinflammation in the PVN with increased SNA. Additionally, intracerebroventricular infusion of minocycline prevents microglial activation, increased SNA and hypertension induced by angiotensin II. 10 Collectively, these findings, led us to propose the following hypothesis: increased activated microglial cells and neuroinflammation in the autonomic regions of the brain are important in PH. They participate in a sequence of physiological events including increased sympathetic activity, plasma norepinephrine, and systemic inflammation to culminate in the development of pulmonary pathophysiology associated with PH. The present study investigated this concept.
Methods

Animals
Authors declare that all supporting data in the article and supplement are available on reasonable request. All animal procedures were approved by the University of Florida Institutional Animal Care and Use Committee. Eight-week-old male SD rats (n=6 to 8 per group) were used and PH was induced by single subcutaneous injection of 50 mg/kg body weight of monocrotaline. A subset of monocrotalineinjected animals was infused intracerebroventricular with minocycline. Four weeks after monocrotaline administration, animals were euthanized for the measurement of physiological and pathological parameters.
Stereotaxic Surgery for Intracerebroventricular Minocycline Infusion
Intracerebroventricular minocycline infusion was performed on the same day as monocrotaline injection. Briefly, rats were anesthetized with isoflurane/O 2 mixture (4%), and the head was fixed in a stereotaxic apparatus (David Kopf Instruments, Tujunga, CA). Body temperature was maintained at 37±1°C using heating pads. A brain infusion cannula was implanted into the left cerebroventricle at coordinates 1.0 caudal to bregma, 1.9 mm lateral to midline and 4.5 mm ventral to the skull surface and fixed to the skull with stainless steel screws and dental cement. The outer end of the cannula was connected to an osmotic minipump (model 2004, Durect Corporation, Cupertino, CA) which was implanted in the neck subcutaneously. Using the cannulae and pumps, either minocycline (5 µg/h; SigmaAldrich, St. Louis, MO) or artificial cerebrospinal fluid (Tocris Bioscience, United Kingdom) was infused for 4 weeks into the left cerebroventricle at a flow rate of 0.25 µL/h. Rats received a single dose of buprenorphine (0.05 mg/kg body weight; Buprenex, Pfizer, NY) subcutaneously during surgery and were monitored daily throughout the experimental period.
Statistical Analysis
For all the parameters, comparisons among the groups were made using 1-way ANOVA, P value <0.05 was accepted as significant and data were presented as mean±SEM. Two-way ANOVA was also used for key parameters to confirm interactions. Full details of all experimental protocols are presented in Methods in the online-only Data Supplement.
Results
Intracerebroventricular Administration of Minocycline Attenuates Monocrotaline-Induced PH Pathophysiology
Our first objective was to determine whether a neuroinflammatory process is involved in monocrotaline-induced PH and whether intracerebroventricular minocycline would influence this process. The rationale for selecting minocycline is its well-documented effects on inhibition of microglial cells and neuroinflammation. 10 As expected, monocrotaline-treated rats had a 153% increase in right ventricular (RV) systolic pressure (30±1.8 mm Hg control rats versus 76±5.3 mm Hg monocrotaline, P<0.001; Figure 1A ) indicative of PH development. Similarly, monocrotaline causes alterations in multiple other hemodynamic parameters such as RV end-diastolic pressure increased 107%, P<0.001; RV +dP/dt increased 86%, P<0.001; and RV −dP/dt decreased 97%, P<0.001 ( Figure 1B through  1D ). Intracerebroventricular minocycline infusion into control rats had no significant effect on any of these parameters. However, intracerebroventricular minocycline infusion into monocrotaline-treated rats reduced RV systolic pressure 34% (50±4.2 mm Hg, P<0.001) versus monocrotaline-treated rats ( Figure 1A ). Furthermore, minocycline beneficially attenuated other hemodynamic parameters ( Figure 1B through 1D ). Echocardiographic analysis documented attenuation of ventricular dilation and maladaptive structural remodeling of the right heart with 63% and 93% improvements in right ventricle/ left ventricle (RV/LV) end-diastolic area and RV/LV ejection fraction when minocycline was administered to monocrotalinetreated rats ( Figure 1E and 1F). Video echocardiographic clips documented an increase in RV/LV in monocrotaline-treated rats versus control rats and rats treated with minocycline alone, implying dilation of the right heart in PH animals (Movies S1A through S1C in the online-only Data Supplement). However, intracerebroventricular minocycline treatment prevented monocrotaline-induced dilation of the right heart (Movie S1D). Monocrotaline caused a significant right heart remodeling as evidenced by a ≈6-fold increase in RV collagen accumulation (P<0.001; Figure 2A and 2B) and ≈2-fold increase in RV hypertrophy (P<0.001, Figure 2C ). Both the parameters were significantly attenuated by intracerebroventricular minocycline treatment (Figure 2A through 2C) . Furthermore, monocrotaline treatment increased pulmonary artery medial wall thickness by ≈2-fold that was significantly attenuated by concomitant treatment with intracerebroventricular minocycline (P<0.001, Figure 3A and 3B). Finally, treatment with minocycline 2 weeks after initiation of PH by monocrotaline showed a significant arrest in the progression of PH-linked hemodynamics in 4 of 6 rats (RV systolic pressure, 70±5.9 mm Hg monocrotaline versus 50±1.5 mm Hg monocrotaline+minocycline [P<0.01, n=4]); RV hypertrophy, 0.43±0.04 monocrotaline versus 0.32±0.01 monocrotaline+minocycline (P<0.05, n=4). Collectively, these observations are the first demonstration of the involvement of brain mechanisms in the development of PH.
Monocrotaline-Induction of Microglial Cells Is Inhibited by Minocycline
Our objective was to answer 2 questions (1) is monocrotalineinduced PH associated with increases in activated microglia and if so, what autonomic brain region(s) is (are) predominantly involved and (2) does minocycline inhibit this process? We observed that monocrotaline-treated rats had a significant increase in total numbers of Iba1 (ionized calcium-binding adaptor molecule 1) positive cells in the PVN of the hypothalamus (Figure 4 ). Iba1 is a marker of mature microglia in the brain. Increases in both the total number (≈2-fold) and number of activated (≈1.5-fold) microglial cells were observed ( Figure 4A through 4C ) in the PVN of monocrotaline-treated rats. Concomitant minocycline and monocrotaline treatments resulted in significant decreases in total number (25%) and a number of activated microglial cells (42%) in the PVN ( Figure 4B and 4C) versus the monocrotaline-treated rats. Increases in the total number of microglial cells were also observed in other autonomic areas such as rostral ventrolateral medulla and nucleus tractus solitarii ( Figure S1A and S1B). However, little change in activated microglial cells was seen in these areas. Furthermore, minocycline treatment had modest effects on total microglial cells but did not influence their activation in these regions in monocrotaline-treated animals ( Figure  S1A and S1B). Movies S2A through S2D are representative examples of 3-dimensional video clips of the same region of PVN from control (S2A), minocycline alone (S2B), monocrotaline-treated (S2C), and monocrotaline with minocycline (S2D) treated rats to fully appreciate the preponderance of microglial cells and their interactions with neurons in monocrotalinetreated rats. The mRNA levels of certain cytokines measured by qPCR confirm the proinflammatory response in the PVN. IL (interleukin)-1β, IL-6, and TNF (tumor necrosis factor)-α mRNAs were increased 54% (P<0.01), 66% (P<0.001), and 260% (P<0.001), respectively, in the PVN of monocrotalinetreated rats ( Figure 5A through 5C ). In contrast, anti-inflammatory IL-10 mRNA levels were decreased by 34% (P<0.05, Figure 5D ). Minocycline treatment of monocrotaline rats significantly attenuated transcription of proinflammatory cytokine genes and increased IL-10. These observations document that monocrotaline treatment is associated with microglial cell activation and neuroinflammation, whereas intracerebroventricular minocycline attenuates these processes.
Restoration of Altered Brain-ANS-Lung Communication in PH by Minocycline
Power spectral analysis of heart rate variability data supported the involvement of sympathetic activation in PH. The ratio of low frequency (LF) and high frequency (HF) is an index for the relationship between sympathetic and parasympathetic nerve activities. 15, 16 Monocrotaline-treated rats had a 108% increase in LF/HF ratio (P<0.001, Figure 6A ) indicating an increase in SNA in PH rats. However, minocycline cotreatment resulted in a complete attenuation of this LF/HF ratio increase (P<0.001, Figure 6A ). These observations are supported by effects of monocrotaline and minocycline on plasma norepinephrine. Monocrotaline treatment increased plasma norepinephrine (135%), whereas minocycline significantly attenuated this increase ( Figure 6B ). Taken together, these observations document that intracerebroventricular minocycline treatment attenuated the enhanced sympathetic activity of monocrotaline-treated rats and suggested an altered PVN regulation of ANS in PH.
Discussion
Our results provide 3 novel observations (1) microglial cell activation and neuroinflammation are associated with PH; (2) increased SNA is associated with vascular remodeling of lung resulting in PH; and (3) intracerebroventricular minocycline infusion decreases microglial cells and microglial activation in the PVN, attenuates SNA, and prevents development of PH. Together, these observations support the suggestion that impaired neuronal-microglial interactions may play a previously unrecognized role in the initiation of the dysfunctional brain-lung communication in PH.
Data for the involvement of neuroinflammation, predominantly in the PVN, are (1) increased microglial cells and proinflammatory cytokines in monocrotaline-treated rats and (2) concomitant intracerebroventricular infusion of minocycline decreased activation of microglial cells, reduced SNA, and improved cardiopulmonary functional parameters to attenuate PH. Minocycline is a broad-spectrum anti-inflammatory antibiotic with rather selective effects to inhibit microglial cells in the brain. 10, 17 Minocycline easily crosses the bloodbrain barrier after oral administration and exerts neuroprotective effects in several diseases involving activated microglial cells. 18, 19 However, the mechanism of its action remains controversial. Direct roles of minocycline on microglial cells include (1) attenuation of NMDA (N-methyl-d-aspartate) toxicity by blocking the NMDA-stimulated activation of p38 MAPK (mitogen-activated protein kinase), an inflammatory mediator expressed on the microglial cells. 19 (2) Inhibition of a specific p38 MAPK inhibitor and prevention of translocation of 5-lipoxygenase into the nucleus consequently blocking the release of cytokines and neuroinflammation. 19 Minocycline's anti-inflammatory effects include inhibition of diverse enzymes (matrix metalloproteinases, phospholipase A2, protein kinase C, cyclooxygenase-2, nitric oxide synthase) and pathways (proinflammatory cytokines, antiapoptotic effects, cell migration, and chemotaxis). 20, 21 Indirect effects on astrocytes, oligodendrocytes, and even on neurons have been suggested to contribute to its protective actions. 22 Thus, anti-PH effects of minocycline on microglial cells likely involve more than one of these signaling pathways. Nonetheless, our observations remain relevant because they are the first demonstration of the involvement of microglial cells in an autonomic brain region in the pathophysiology of PH.
Minocycline exerts strong anti-inflammatory effects, thus the possibility of its direct protective effect on lung inflammation cannot be excluded. It is conceivable that some intracerebroventricular-administered minocycline diffuses to the peripheral circulation to influence lung vasculature. This view is supported by the observations that minocycline attenuates pulmonary fibrosis in mice. 23 However, we think that this is a less likely possibility in our experimental paradigm as we used a significantly lower concentration of minocycline. Furthermore, effective concentrations of systemic minocycline in pulmonary disorders such as pulmonary fibrosis were significantly higher. 23 In the present study, to ensure that the observed effects were because of intracerebroventricular infusion of minocycline, we verified cannula placement by microscopic visualization of the tract. Animals whose cannulae were misplaced did not respond to minocycline treatment; their data were not included in the results. Thus, their nonresponsiveness argues against a systemic effect of this dose of minocycline. Even so, the possibility of indirect effects of minocycline, such as influence on astrocytes, neurons or peripheral-generated cytokines, can also not be ruled out from this study.
Peripheral inflammation impacts PH pathophysiology because circulating inflammatory markers and infiltration of inflammatory cells have been observed within lung tissue during PH. 24 However, a role for inflammation within the central nervous system in PH has never been investigated. How neuroinflammation is triggered in the central nervous system and modulates SNA to perpetuate PH is quite unclear and under active investigation. Evidence indicates that activated microglia release several proinflammatory cytokines, 10 and reactive oxygen species 25 within the central nervous system. These inflammatory processes alone or in combination, increase the activity of PVN neurons converging on rostral ventrolateral medulla and resulted in increased sympathetic outflow to the periphery. Importantly, in a separate unpublished study, we observed increased activated microglial cells in the PVN of mice with hypoxia-induced PH, further supporting the existence of an interplay between the central nervous system and PH.
These observations suggest altered autonomic-lung communication in PH. Evidence for this includes the following (1) increased ratio of LF and HF components (LF/HF ratio; represents a measure of sympathovagal balance) observed in monocrotaline-induced PH rats and (2) increased plasma norepinephrine commonly attributed to increased sympathetic drive. Moreover, these elevated autonomic indices were attenuated by intracerebroventricular infusion of minocycline.
Our observations, coupled with existing evidence, leads us to propose the following hypothesis: we suggest that diverse propulmonary hypertensive signals (environmental, genetics, etc) are perceived by PVN neurons whose chemical and physical interactions with resident microglia cells cause their activation. This activated the neuronal-microglial unit, with increased cytokines, neuronal activity, etc, increases SNA to the lung, increases inflammatory status, and imbalances plasma metabolites and cytokines. Together, these products impact the lung vasculature, leading to pulmonary pathophysiology associated with PH. Of course, this is a working hypothesis, but our study presents key data to support the concept.
However, many more questions remain for further investigation. They are (1) is the activity of pulmonary sympathetic nerves altered in PH? (2) Do different autonomic brain regions integrate to mediate effects on pulmonary pathophysiology, and by what mechanism? (3) Which actions of minocycline protect in PH, antibiotic, anti-inflammatory, or both? (4) Is activation of microglial cells in the PVN because of the direct effect of monocrotaline or indirectly via monocrotaline-stimulated inflammatory mediators? This seems rather unlikely because there is no clear evidence of blood-brain barrier permeability of monocrotaline. (5) The monocrotaline rat model used in this study was selected because it represents a complex multiorgan disease process that culminates in PH and right heart failure, a concept that we have attempted to test here. However, we acknowledge its limitations and the brain-ANS-lung hypothesis must be investigated with other models of PH and in human PH. Nonetheless, lacking answers to these questions now should not minimize the importance of our novel observations, which provide the prerequisites to evaluate translational implications of the disordered brain-ANS-lung communication in PH patients.
Perspectives
Significant evidence exist explaining lung pathophysiology in PH, such as endothelial cell dysfunction, smooth muscle cell proliferation, vascular inflammation, immune dysregulation, and certain genetic determinants. Most current therapies are centered on these mechanisms. Despite considerable advances, the survival of PH patients remains poor. We considered whether PH is a disease with complex interactions of many organ systems ultimately affecting lungs. The present study demonstrated that central administration of minocycline, an anti-inflammatory antibiotic and inhibitor of microglial cells, inhibited microglial activation, reduced neuroinflammation, restored autonomic imbalance and prevented PH-associated pathologies in the monocrotaline-induced rat model of PH. Thus, these results may present novel therapeutic targets for PH treatment.
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